IRTC · Irhythm Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $747.14M | $591.84M | $492.68M | $410.92M | $322.82M | $265.17M |
| Cost of Revenue | $219.89M | $184.31M | $160.88M | $129.29M | $109.26M | $70.28M |
| Gross Profit | $527.25M | $407.53M | $331.81M | $281.63M | $213.57M | $194.89M |
| R&D | $84.61M | $71.46M | $60.24M | $46.61M | $38.67M | $41.33M |
| SG&A | $492.55M | $418.56M | $385.64M | $322.20M | $274.84M | $197.23M |
| Total Operating Expenses | $584.66M | $523.04M | $456.97M | $395.42M | $313.51M | $238.56M |
| D&A | $20.70M | $20.70M | $16.30M | $6.90M | $9.84M | $6.90M |
| Operating Income | ($57.41M) | ($115.50M) | ($125.16M) | ($113.78M) | ($99.94M) | ($43.67M) |
| Interest Expense | $13.15M | $12.82M | $3.65M | $4.14M | $1.17M | $1.52M |
| Income Tax | $953.0K | $565.0K | $750.0K | $269.0K | $367.0K | $229.0K |
| Net Income | ($44.55M) | ($113.29M) | ($123.41M) | ($116.16M) | ($101.36M) | ($43.83M) |
| EPS - Basic | ($1.39) | ($3.63) | ($4.04) | ($3.88) | ($1.58) | - |
| EPS - Diluted | ($1.39) | ($3.63) | ($4.04) | ($3.88) | ($1.58) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $236.01M | $419.60M | $36.17M | $78.83M | $127.56M | $88.63M |
| Accounts Receivable | $75.71M | $79.94M | $61.48M | $49.92M | $46.43M | $29.93M |
| Inventory | $21.63M | $14.04M | $13.97M | $15.15M | $10.27M | $5.31M |
| Accounts Payable | $2.26M | $7.22M | $5.54M | $7.52M | $10.51M | $4.37M |
| Current Assets | $702.76M | $645.82M | $230.81M | $288.77M | $305.52M | $377.82M |
| Total Assets | $1.02B | $931.45M | $433.14M | $448.22M | $462.97M | $511.74M |
| Current Liabilities | $151.89M | $110.92M | $107.37M | $89.10M | $87.85M | $65.67M |
| Long-term Debt | - | - | $34.95M | $34.94M | $9.69M | $21.34M |
| Total Liabilities | $867.30M | $840.54M | $223.05M | $208.41M | $183.45M | $170.13M |
| Stockholders' Equity | $152.75M | $90.91M | $210.10M | $239.81M | $279.51M | $341.61M |
| Retained Earnings | ($803.45M) | ($758.89M) | ($645.61M) | ($522.20M) | ($406.05M) | ($304.68M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $80.86M | $3.39M | ($50.10M) | ($23.01M) | ($37.75M) | ($13.76M) |
| Investing Cash Flow | ($277.06M) | ($122.98M) | ($1.21M) | ($52.43M) | $105.26M | ($132.39M) |
| Financing Cash Flow | $12.61M | $511.38M | $8.82M | $26.72M | ($28.58M) | $214.32M |
| CapEx | $46.34M | $33.94M | $40.42M | $29.83M | $28.07M | $13.55M |
| Free Cash Flow | $34.52M | ($30.55M) | ($90.53M) | ($52.84M) | ($65.82M) | ($27.31M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 70.6% | 68.9% | 67.3% | 68.5% | 66.2% | 73.5% |
| Operating margin | -7.7% | -19.5% | -25.4% | -27.7% | -31.0% | -16.5% |
| EBITDA margin | -4.9% | -16.0% | -22.1% | -26.0% | -27.9% | -13.9% |
| Net margin | -6.0% | -19.1% | -25.0% | -28.3% | -31.4% | -16.5% |
| Free cash flow margin | 4.6% | -5.2% | -18.4% | -12.9% | -20.4% | -10.3% |
| FCF / Net income | -0.77 | 0.27 | 0.73 | 0.45 | 0.65 | 0.62 |
| R&D / Revenue | 11.3% | 12.1% | 12.2% | 11.3% | 12.0% | 15.6% |
| SG&A / Revenue | 65.9% | 70.7% | 78.3% | 78.4% | 85.1% | 74.4% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -4.4% | -12.2% | -28.5% | -25.9% | -21.9% | -8.6% |
| Return on equity | -29.2% | -124.6% | -58.7% | -48.4% | -36.3% | -12.8% |
| Return on invested capital | - | - | -40.4% | -32.7% | -27.3% | -9.5% |
| Liquidity | ||||||
| Current ratio | 4.63 | 5.82 | 2.15 | 3.24 | 3.48 | 5.75 |
| Quick ratio | 4.48 | 5.70 | 2.02 | 3.07 | 3.36 | 5.67 |
| Cash ratio | 1.55 | 3.78 | 0.34 | 0.88 | 1.45 | 1.35 |
| Leverage | ||||||
| Debt / Equity | - | - | 0.17 | 0.15 | 0.03 | 0.06 |
| Debt / Assets | - | - | 0.08 | 0.08 | 0.02 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -4.4x | -9.0x | -34.3x | -27.5x | -85.5x | -28.8x |
| Equity multiplier | 6.68 | 10.25 | 2.06 | 1.87 | 1.66 | 1.50 |
| Liabilities / Assets | 0.85 | 0.90 | 0.51 | 0.46 | 0.40 | 0.33 |
| Efficiency | ||||||
| Asset turnover | 0.73 | 0.64 | 1.14 | 0.92 | 0.70 | 0.52 |
| Inventory turnover | 10.16 | 13.13 | 11.51 | 8.53 | 10.64 | 13.23 |
| Days sales outstanding | 37d | 49d | 46d | 44d | 52d | 41d |
| Days inventory outstanding | 36d | 28d | 32d | 43d | 34d | 28d |
| Days payable outstanding | 4d | 14d | 13d | 21d | 35d | 23d |
| Cash conversion cycle | 69d | 63d | 65d | 66d | 52d | 46d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 37.2x | 30.9x | 15.6x | 11.7x | 11.7x | - |
| P / S | 7.6x | 4.8x | 6.6x | 6.8x | 10.1x | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 26.2% | 20.1% | 19.9% | 27.3% | 21.7% | 23.6% |
| Revenue CAGR (3y) | 22.1% | 22.4% | 22.9% | 24.2% | 71.4% | 39.1% |
| Revenue CAGR (5y) | 23.0% | 22.5% | 50.4% | 33.1% | 38.2% | - |
| Gross profit growth (YoY) | 29.4% | 22.8% | 17.8% | 31.9% | 9.6% | 20.3% |
| Operating income growth (YoY) | 50.3% | 7.7% | -10.0% | -13.8% | -128.8% | 20.2% |
| Net income growth (YoY) | 60.7% | 8.2% | -6.2% | -14.6% | -131.3% | 19.7% |
| EPS growth (YoY) | 61.7% | 10.1% | -4.1% | -145.6% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | 66.3% | -71.3% | 19.7% | -141.0% | 35.5% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 68.0% | -56.7% | -12.4% | -14.2% | -18.2% | 152.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$747.14M totalCommercial Payors$392.23M · 52.5%
Centers For Medicare And Medicaid$179.35M · 24.0%
Healthcare Institutions$125.61M · 16.8%
Non Contracted Third Party Payors$49.94M · 6.7%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.35
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing iRhythm Holdings against the 5 most active filers in the same SIC group.